NDA 022474 · Lab Hra Pharma
Ella
Ulipristal Acetate · Oral
NovelLast checked: Nov 20, 2026Latest source record: Jun 24, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2010
Aug 13, 2010
Approved uses
2
Original approval plus efficacy supplements
Registered trials
69
16 Phase 3, 3 recruiting
FAERS reports
512
456 serious, 2 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 20, 2026.
Ella is a progesterone agonist/antagonist emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure [see Dosage and Administration (2.1) ] . Ella is not intended for routine use as a contraceptive. Ella is a progesterone agonist/antagonist emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. Ella is not intended for routine use as a contraceptive. ( 1 )
Mechanism: When taken immediately before ovulation is to occur, ella postpones follicular rupture. The likely primary mechanism of action of ulipristal acetate for emergency contraception is therefore inhibition or delay of ovulation; however, alterations to the endometrium that may affect implantation may also contribute to efficacy.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 24, 2021 Supplement 11 · Efficacy LetterLabel
- Aug 13, 2010 Original approval · Type 1 - New Molecular Entity NovelLabelPediatric Medical ReviewPediatric Clinical Pharmacology Review
1 products under this application
- ELLA · ULIPRISTAL ACETATE 30MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Ulipristal" as an intervention, any sponsor and status, largest first.
- Safety and Efficacy of CDB-2914 in Comparison to Levonorgestrel for Emergency ContraceptionPivotal-lookingCompleted
HRA PharmaIndustry
NCT00551616 · 2,221 participants · Start Apr 2007 · Primary completion Apr 2009
Drug: CDB-2914; Levonorgestrel · For: Contraception
Sites: Los Angeles, California; Santa Monica, California; Boulder, Colorado · 33 sites in all
- Efficacy Trial of CDB 2914 for Emergency ContraceptionPivotal-lookingCompleted
University of PittsburghAcademic, hospital or other
NCT00271583 · 1,672 participants · Start Sep 1999
Drug: CDB-2914; levonorgestrel · For: Emergency Contraception
Sites: Los Angeles, California; Denver, Colorado; New York, New York · 6 sites in all
- Safety and Efficacy of CDB-2914 for Emergency ContraceptionPivotal-lookingCompleted
HRA PharmaIndustry
NCT00411684 · 1,623 participants · Start Nov 2006 · Primary completion Apr 8, 2008
Drug: CDB-2914 · For: Emergency Contraception
Sites: San Jose, California; Denver, Colorado; Miami, Florida · 17 sites in all
- A Study of Use of Ella®, an Emergency Contraceptive, Under Simulated OTC ConditionsPivotal-lookingCompleted
HRA PharmaIndustry
NCT03208985 · 1,270 participants · Start May 23, 2017 · Primary completion Jun 14, 2018
Drug: Use Phase (Ulipristal Acetate, 30 mg) · For: Emergency Contraception
Sites: Rancho Cucamonga, California; Boulder, Colorado; Denver, Colorado · 34 sites in all
- Levonorgestrel-piroxicam Versus Ulipristal Acetate for Emergency ContraceptionPivotal-lookingRecruiting
The University of Hong KongAcademic, hospital or other
NCT06727734 · 980 participants (planned) · Start Jan 18, 2025 · Primary completion Sep 2027
Drug: Levonorgestrel; Piroxicam and 4 more · For: Contraception
Sites: Hong Kong, Hong Kong
- Study Comparing Emergency Contraception Effectiveness in Women Who Weight ≥ 80 kgPivotal-lookingTerminated
Kimberly MyerAcademic, hospital or other
NCT03537768 · 532 participants · Start Jul 12, 2018 · Primary completion Apr 20, 2022
Drug: Ulipristal Acetate; Levonorgestrel and 1 more · For: Contraception
Sites: Los Angeles, California; Sacramento, California; San Francisco, California · 18 sites in all
- PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine LeiomyomataPivotal-lookingCompleted
PregLem SAIndustry
NCT01629563 · 451 participants · Start Jun 2012 · Primary completion Jan 2015
Drug: PGL4001 5 mg; PGL4001 10 mg · For: Uterine Fibroids
Sites: Brussels, Belgium; Leuven, Belgium; Liège, Belgium · 49 sites in all
- A Study of the Efficacy and Safety of Ulipristal Acetate Intermittent Treatment for Abnormal Uterine Bleeding Associated With LeiomyomasPivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT02147158 · 432 participants · Start Jan 29, 2014 · Primary completion Nov 24, 2016
Drug: Ulipristal acetate (UPA); Placebo · For: Leiomyoma; Uterine Hemorrhage
Sites: Mesa, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 63 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- unintended pregnancy149
- abortion spontaneous108
- vaginal haemorrhage74
- drug ineffective54
- nausea39
- pregnancy after post coital contraception36
- abdominal pain28
- headache27
- dizziness26
- exposure during pregnancy24
- maternal exposure during pregnancy22
- abortion induced21
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2011 | 3 |
| 2012 | 35 |
| 2013 | 12 |
| 2014 | 17 |
| 2015 | 18 |
| 2016 | 40 |
| 2017 | 72 |
| 2018 | 60 |
| 2019 | 35 |
| 2020 | 23 |
| 2021 | 21 |
| 2022 | 41 |
| 2023 | 43 |
| 2024 | 33 |
| 2025 | 36 |
| 2026 | 23 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- [Emergency contraception.].
Lczi L, Vezér M, Török M, et al. · Orv Hetil 2023 · Systematic Review, English Abstract
- Preoperative medical therapy before surgery for uterine fibroids.
Puscasiu L, Vollenhoven B, Nagels HE, et al. · Cochrane Database Syst Rev 2025 · Systematic Review, Meta-Analysis
- Management of bleeding irregularities during contraceptive implant use: A systematic review.
Cohen MA, Snyder EM, Curtis KM, et al. · Contraception 2026 · Systematic Review
- Interventions for emergency contraception.
Shen J, Che Y, Showell E, et al. · Cochrane Database Syst Rev 2019 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Interventions for emergency contraception.
Cheng L, Che Y, Gülmezoglu AM · Cochrane Database Syst Rev 2012 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Interventions for emergency contraception.
Shen J, Che Y, Showell E, et al. · Cochrane Database Syst Rev 2017 · Meta-Analysis, Systematic Review
Sponsor: Lab Hra Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.